GlassScriptPhysician profile
Mohammad Amjadullah Khan
NPI 1568667251
$2,341.45
in general payments reported to CMS, 2019-2025
17 companies · $914 in 2025
The $914 reported for 2025 was more than what 80% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $597 · 2024: $831 · 2025: $914.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,341.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,341.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $624.61 | 2023-2025 | Rexulti, Nuedexta |
| Corium, LLC | $373.38 | 2023-2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $308.42 | 2023-2025 | Caplyta |
| Axsome Therapeutics, INC. | $271.75 | 2023-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $169.00 | 2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $101.79 | 2024 | |
| Neuronetics, INC. | $86.91 | 2023-2024 | Neurostar Tms Therapy System |
| Lundbeck LLC | $82.81 | 2024-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $61.01 | 2025 | Qelbree |
| Tris Pharma INC | $60.95 | 2023-2025 | Dyanavel Xr |
| Vertical Pharmaceuticals, LLC | $49.18 | 2025 | Relexxii |
| Collegium Pharmaceutical, INC. | $41.11 | 2025 | Jornay Pm |
| Neurocrine Biosciences, INC. | $28.66 | 2023 | Ingrezza |
| Janssen Pharmaceuticals, INC | $25.66 | 2025 | Spravato |
| Avion Pharmaceuticals | $20.82 | 2023 | Methylphenidate Hydrochloride |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $20.80 | 2025 | |
| Biogen, INC. | $14.59 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.